MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Trametinib (Primary)
- Indications Leukaemia; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 20 Jul 2017 Planned End Date changed from 1 Jun 2018 to 31 Dec 2017.
- 20 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 31 Aug 2017.
- 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.